Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Stopped early · Phase 1/Phase 2

Conditions studied: Non-Hodgkins Lymphoma

In brief

The purpose of this study is to determine the optimal dose of Campath for patients with relapsing or refractory (failed standard therapy) non-Hodgkin's lymphoma. The study will also evaluate the safety of the drug and whether it is effective in treating these patients.

Key facts

Study ID

NCT00051701

Run by

Genzyme, a Sanofi Company

People needed

61

Starts

2002-12-01

Expected to finish

2005-08-01

Last updated by the study team

2015-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Aurora, Colorado, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — Denver, Colorado, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Overland Park, Kansas, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Kansas City, Missouri, United States
• Study site — Santa Fe, New Mexico, United States
• Study site — Dayton, Ohio, United States
• Study site — Tulsa, Oklahoma, United States
• Study site — Dallas, Texas, United States
• Study site — Fort Worth, Texas, United States
• Study site — Plano, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Tyler, Texas, United States
• Study site — Spokane, Washington, United States
• Study site — Vancouver, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.